Chairman’s address
Torreya processIn February, we appointed Torreya, a global investment bank specialising in life sciences, as Neuren’s corporate advisor. Our objective is to evaluate all potential corporate transactions, be it for individual products, defined territories, or Neuren’s entire business. A formal process commenced in April and we are well advanced in terms of engaging with third parties in the US, Europe and Japan. Our expectation at this stage is that the process will complete in Q3 2019.
Ann: New patent granted for Neuren's NNZ-2591 in Japan, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.70 |
Change
0.220(1.33%) |
Mkt cap ! $2.104B | |||
| Open | High | Low | Value | Volume |
| $16.65 | $16.90 | $16.33 | $5.569M | 332.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1333 | $16.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.78 | 30 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |